MARCO ARESE

Prof. MARCO ARESE

orcid

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 1999 in Molecular Biology of the Cell
Verified
Journal Article
Closed access
MAMARCO ARESE
MARCO ARESE
YCYan Chen
Yan Chen
RFRobert Z. Florkiewicz
Robert Z. Florkiewicz
AGAnna Gualandris
Anna Gualandris
BSBin Shen
Bin Shen
DRDaniel B. Rifkin
Daniel B. Rifkin
Human basic fibroblast growth factor (FGF-2) occurs in four isoforms: a low molecular weight (LMW FGF-2, 18 kDa) and three high molecular weight (HMW FGF-2, 22, 22.5, and 24 kDa) forms. LMW FGF-2 is primarily cytoplasmic and functions in an autocrine manner, whereas HMW FGF-2s are nuclear and exert activities through an intracrine, perhaps nuclear, pathway. Selective overexpression of HMW FGF-2 forms in fibroblasts promotes growth in low serum, whereas overexpression of LMW FGF-2 does not. The HMW FGF-2 forms have two functional domains: an amino-terminal extension and a common 18-kDa amino acid sequence. To investigate the role of these regions in the intracrine signaling of HMW FGF-2, we produced stable transfectants of NIH 3T3 fibroblasts overexpressing either individual HMW FGF-2 forms or artificially nuclear-targeted LMW FGF-2. All of these forms of FGF-2 localize to the nucleus/nucleolus and induce growth in low serum. The nuclear forms of FGF-2 trigger a mitogenic stimulus under serum starvation conditions and do not specifically protect the cells from apoptosis. These data indicate the existence of a specific role for nuclear FGF-2 and suggest that LMW FGF-2 represents the biological messenger in both the autocrine/paracrine and intracrine FGF-2 pathways.

1 August 1995 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
FBFederico Bussolino
Federico Bussolino
MAMARCO ARESE
MARCO ARESE
GMG Montrucchio
G Montrucchio
LBL Barra
L Barra
LPL Primo
L Primo
MRM R Rola-Pleszczynski
M R Rola-Pleszczynski
Imbalance in the network of soluble mediators may play a pivotal role in the pathogenesis of Kaposi's sarcoma (KS). In this study, we demonstrated that KS cells grown in vitro produced and in part released platelet activating factor (PAF), a powerful lipid mediator of inflammation and cell-to-cell communication. IL-1, TNF, and thrombin enhanced the synthesis of PAF. PAF receptor mRNA and specific, high affinity binding site for PAF were present in KS cells. Nanomolar concentration of PAF stimulated the chemotaxis and chemokinesis of KS cells, endothelial cells, and vascular smooth muscle cells. The migration response to PAF was inhibited by WEB 2170, a hetrazepinoic PAF receptor antagonist. Because neoangiogenesis is essential for the growth and progression of KS and since PAF can activate vascular endothelial cells, we examined the potential role of PAF as an instrumental mediator of angiogenesis associated with KS. Conditioned medium (CM) from KS cells (KS-CM) or KS cells themselves induced angiogenesis and macrophage recruitment in a murine model in which Matrigel was injected subcutaneously. These effects were inhibited by treating mice with WEB 2170. Synthetic PAF or natural PAF extracted from plasma of patients with classical KS also induced angiogenesis, which in turn was inhibited by WEB 2170. The action of PAF was amplified by expression of other angiogenic factors and chemokines: these included basic and acidic fibroblast growth factor, placental growth factor, vascular endothelial growth factor and its specific receptor flk-1, hepatocyte growth factor, KC, and macrophage inflammatory protein-2. Treatment with WEB 2170 abolished the expression of the transcripts of these molecules within Matrigel containing KS-CM. These results indicate that PAF may cooperate with other angiogenic molecules and chemokines in inducing vascular development in KS.

1 January 2004 in Blood
Verified
Journal Article
Closed access
PDF file
MSMarina Strasly
Marina Strasly
GDGabriella DORONZO
Gabriella DORONZO
Paola CappelloPaola Cappello
Paola Cappello
DVDonatella Valdembri
Donatella Valdembri
MAMARCO ARESE
MARCO ARESE
FBFederico Bussolino
Federico Bussolino
Besides regulating leukocyte trafficking in normal and injured tissues, several chemokines may positively or negatively regulate angiogenesis. Here we report that CCL16 activates an angiogenic program in vascular endothelial cells by activating CCR1. CCL16 induces dose-dependent random and directional migration of endothelial cells isolated from large vessels and liver capillaries without inducing their proliferation. It also promotes endothelial differentiation into capillary-like structures in an in vitro assay and is angiogenic in the chick chorionallantoic membrane. These angiogenic activities are neutralized by a specific antibody against CCL16. The direct angiogenic activity of CCL16 is further amplified by its ability to prime endothelium to a mitogen signal induced by vascular endothelial growth factor A and to raise their basal production of CXCL8 and CCL2, 2 other angiogenic chemokines. BX471 (R-N-[5-chloro-2-[2-[4(4-fluorophenyl) methyl]-2-methyl-1-piperazinyl]-2-oxoethoxy]phenyl] urea hydrochloric acid salt), a CCR1 antagonist, inhibits angiogenic properties of CCL16, whereas blocking of CCR8 or desensitizing CCR2, which are both well known receptors for CCL16, did not abolish endothelial activation. CCL16 may be specifically cross-linked to CCR1 expressed on endothelial cells. The largely restricted CCL16 expression in the liver suggests that this chemokine may play a role in hepatic vascular formation during development and in angiogenesis associated to hepatic diseases.

15 June 1995 in The Journal of Immunology
Verified
Journal Article
Open access
PDF file
GCGiovanni Camussi
Giovanni Camussi
GMG Montrucchio
G Montrucchio
ELE Lupia
E Lupia
AMA De Martino
A De Martino
LPL Perona
L Perona
FBFederico Bussolino
Federico Bussolino
The aim of the present study was to investigate the angiogenic properties of platelet-activating factor (PAF). In vitro PAF was shown to induce a dose-dependent migration of human endothelial cells (EC) across the polycarbonate filters in Boyden's chambers. In contrast, d-PAF, the biologically inactive enantiomer, and Lyso-PAF did not stimulate a significant migration of EC. This effect of PAF was not associated with a proliferative response of EC to this mediator. Moreover, the ability of PAF to stimulate the migration of EC was independent of the presence of heparin in the medium. WEB 2170, a specific PAF receptor antagonist, prevented the migration of EC induced by PAF, thus suggesting a receptor-dependent stimulation. The expression of PAF receptor gene by EC was confirmed by reverse transcriptase-PCR and Southern blot analysis. The in vivo angiogenic effect of PAF was studied in mice using a model in which Matrigel was used for the delivery of mediators. PAF induced a dose-dependent angiogenic response, which at pharmacologic concentrations (1-5 microM) did not require heparin, but at physiologic concentrations (5-50 nM) required the presence of heparin at doses that were not angiogenic per se. The angiogenesis induced by 50 nM PAF was, indeed, inhibited both by protamine and by the PAF receptor antagonist WEB 2170. The angiogenic effect of D-PAF and Lyso-PAF was not significant. Neutralizing Abs to basic fibroblast growth factor induced a slight but not statistically significant reduction of the angiogenesis induced by PAF.

1 November 1995 in Arteriosclerosis, Thrombosis, and Vascular Biology
Verified
Journal Article
Closed access
PDF file
FSFrancesca Silvagno
Francesca Silvagno
Antonia FollenziAntonia Follenzi
Antonia Follenzi
MAMARCO ARESE
MARCO ARESE
MPMaria Prat
Maria Prat
Enrico GiraudoEnrico Giraudo
Enrico Giraudo
FBFederico Bussolino
Federico Bussolino
Hepatocyte growth factor (HGF) is a powerful motogen and mitogen for epithelial cells. The factor is a 90-kD heterodimer composed of an α chain containing four kringle motifs and a β chain showing structural homologies with serine proteases. It is, however, devoid of enzymatic activity. Recently, it has been reported that HGF activates migration and proliferation of endothelial cells and is angiogenic. In this article we discuss (1) the molecular domains of HGF required to activate in vitro and in vivo endothelial cells, studied by use of molecular mutants, and (2) the characteristics of the angiogenic response to HGF in an experimental model system of implanted reconstituted basement membrane (Matrigel). Two groups of mutants were made and used in vitro and in vivo: one with deletions of kringle domains and one with substitution at the cleavage site of the HGF precursor. In vitro, HGF variants containing only the first two (HGF-NK2) or the first three kringles (HGF-NK3) of the α chain did not induce proliferation of endothelial cells even if used at a concentration 160-fold higher than that optimal for HGF (0.05 nmol/L). High concentrations of these mutants (4 to 8 nmol/L) activated a little endothelial cell motogenic response that was 60% lower than that elicited by HGF. Substitution of Arg 489 with Gln 489 in the HGF precursor generated an uncleavable single-chain factor, unable to induce either endothelial cell migration or proliferation. In vivo, HGF induced a dose-dependent angiogenic response, which was enhanced by heparin. Optimal HGF concentration (0.42 nmol/L) induced the appearance of clusters of migrating endothelial cells after 2 days. Canalized vessels appeared after 4 days, and the angiogenic response was completed within 6 days with full vascularization of the implanted Matrigel plug. HGF-NK2 and HGF-NK3 did not induce angiogenesis when used at equimolar, biologically active HGF concentrations. A little angiogenic response was observed at a concentration 10-fold higher than that of HGF. The uncleavable single-chain molecule was devoid of activity. The transcript of the HGF receptor was present in the Matrigel plug containing HGF, and the angiogenic response involved its activation, as shown by the agonist effect elicited by a monoclonal antibody against the extracellular domain of the receptor. Furthermore, [3-(1,4,-dihydroxytetralyl)-methylene-2-oxindole], a novel tyrosine kinase inhibitor effective on the HGF receptor, inhibited HGF-induced angiogenesis. During the formation of the new vessels, HGF induces expression of other angiogenic factors and chemokines: these include placental growth factor, vascular endothelial growth factor, KC, JE, macrophage inflammatory protein–2, and HGF itself. A neutralizing antibody to vascular endothelial growth factor partially prevented the angiogenesis induced by HGF. The results of this study demonstrate that the angiogenic response induced by HGF in vivo is elicited by stimulation of the HGF receptor, requires the presence of both α and β chains, and is amplified by other molecules, including vascular endothelial growth factor.

8 December 2009 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
ABAlessia Bottos
Alessia Bottos
EDErika Destro
Erika Destro
ARAlberto Rissone
Alberto Rissone
SGStefania Graziano
Stefania Graziano
GCGabriele Cordara
Gabriele Cordara
MAMARCO ARESE
MARCO ARESE
Unlike other neuronal counterparts, primary synaptic proteins are not known to be involved in vascular physiology. Here, we demonstrate that neurexins and neuroligins, which constitute large and complex families of fundamental players in synaptic activity, are produced and processed by endothelial and vascular smooth muscle cells throughout the vasculature. Moreover, they are dynamically regulated during vessel remodeling and form endogenous complexes in large vessels as well as in the brain. We used the chicken chorioallantoic membrane as a system to pursue functional studies and demonstrate that a monoclonal recombinant antibody against β-neurexin inhibits angiogenesis, whereas exogenous neuroligin has a role in promoting angiogenesis. Finally, as an insight into the mechanism of action of β-neurexin, we show that the anti-β-neurexin antibody influences vessel tone in isolated chicken arteries. Our finding strongly supports the idea that even the most complex and plastic events taking place in the nervous system (i.e., synaptic activity) share molecular cues with the vascular system.